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Abstract
The occurrence of acute promyelocytic leukemia (APL)
in HIV-infected patients has been reported in only five
cases. Due to a very small number of reported
HIV/APL patients who have been treated with differ-
ent therapies with the variable outcome, the prognosis
of APL in the setting of the HIV-infection is unclear.
Here, we report a case of an HIV-patient who devel-
oped APL and upon treatment entered a complete re-
mission. A 25-years old male patient was diagnosed
with HIV-infection in 1996, but remained untreated. In
2004, the patient was diagnosed with primary central
nervous system lymphoma. We treated the patient with
antiretroviral therapy and whole-brain irradiation, re-
sulting in complete remission of the lymphoma. In
2006, prompted by a sudden neutropenia, we carried
out a set of diagnostic procedures, revealing APL. In-
duction therapy consisted of standard treatment with
all-trans-retinoic-acid (ATRA) and idarubicin. Subse-
quent cytological and molecular analysis of bone mar-
row demonstrated complete hematological and molecu-
lar remission. Due to the poor general condition, con-
solidation treatment with ATRA was given in March
and April 2007. The last follow-up 14 months later,
showed sustained molecular APL remission. In conclu-
sion, we demonstrated that a complete molecular APL
remission in an HIV-patient was achieved by using re-
duced-intensity treatment.
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TO THE EDITOR
When compared with the general population, the inci-
dence of acute myeloid leukemia in HIV-infected pa-
tients is increased approximately twofold [1]. Howev-
er, occurrence of acute promyelocytic leukemia (APL)
has so far been reported in only five HIV-infected pa-
tients. [1, 2, 3, 4] Here, we report a case of an HIV-pa-
tient who developed APL and upon treatment entered
a complete remission.
A 25-year-old bisexual, Caucasian male patient was
diagnosed with HIV infection in 1996. He was still an-
tiretroviral naïve in April 2004 when primary central
nervous system lymphoma (PCNSL) was diagnosed by
brain biopsy. We treated the patient with HAART
(highly active antiretroviral treatment) consisting of zi-
dovudine, lamivudine and lopinavir/ritonavir, and
whole brain irradiation with 46 Gy. The therapy result-
ed in durable remission of the lymphoma. Before we
started with HAART, the patients CD4 cell count was
7 cells/mm3 and his plasma HIV-1 RNA was 329.000
copies/ml. Thirty months later, in October 2006, pa-
tient’s WBC was 1,6x109/L, hemoglobin level 109g/L
and platelet counts 28 x 109/L. Physical examination
was unremarkable. Bone marrow aspiration revealed
massive infiltration of blasts, morphologically de-
scribed as promyelocytes, and expressed the immuno-
phenotypic markers of aberrant promyelocytic clone
(CD15-CD117+CD34-HLD-DR-). FISH analysis of
the bone marrow aspirate showed chromosomal
translocation specific for APL, t(15;17), and cytoge-
netic analysis failed. PCR analysis detected an atypical
PML/RARα rearrangement of 470 bp, which was
confirmed by gene sequencing. Based on these results
we diagnosed APL. At the time of APL diagnosis, pa-
tient’s CD4 cell count was 184 cells/mm3 and the plas-
ma HIV-1 RNA viral load was < 50 copies/ml.
In November 2006, we started a treatment accord-
ing to the standard protocol for APL. Induction thera-
py consisted of all-trans retinoic acid (ATRA) in dose
of 45 mg/m2/day taken orally for 34 days, and idaru-
bicine in dose 12mg/m2/day intravenously through 4
days. During neutropenia treatment was complicated
by sepsis. However, signs suggestive of the APL dif-
ferentiation syndrome (ATRA syndrome or retinoic
acid syndrome) such as pulmonary infiltrates or leuko-
cytosis were not observed. Because of pancytopenia
and the poor general condition of the patient, we in-
terrupted HAART for a period of two months. A de-
crease of CD4 cell count to 47 cells/mm3 and increase
of plasma HIV-1 viral load to 394.000 copies/ml was
observed in December 2006. HAART with stavudine,
lamivudine and lopinavir/ritonavir was started on De-
cember 28, 2006. In February 2007, analysis of bone
marrow aspirate and PCR analysis for the PML/RARα
indicated complete molecular remission. Given the pa-
tients poor compliance along with severe side-effects
of earlier treatments and low performance status, we
decided to continue consolidation treatment with sole-
ly ATRA. ATRA was given during March and April
2007 as two cycles of 45 mg/m2/day for 42 days. In
November 2007, we confirmed a sustained complete
molecular remission. On the last follow-up in April
2008, the patient was still in complete hematological
remission, and no signs of PCNSL were observed ei-
ther. Plasma HIV-1 viral load was less then 50 copies
of RNA per milliliter.
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py for APL, CD4 cell counts and viral load measure-
ments are summarized in Figure 1.
APL usually occurs de novo. However, a subgroup
of patients has been described that developed APL
following various chemotherapy- or radiotherapy-
treated malignancies [5]. An atypical PML/RARα re-
arrangement found in our patient, and the fact that
APL occurred 30 months after PCNSL, in a time
frame characteristic for treatment-related APL, indi-
cates that APL might have developed secondary to
treatment of PCNSL. The treatment outcome of ther-
apy-related APL is similar to de novo APL [5]. Howev-
er, due to only five reported cases, the prognosis and
course of APL in HIV-infected patients are unclear. In
those reported cases, patient treated with the com-
bined therapy of ATRA and chemotherapy entered a
remission [1, 2, 3, 4, 5]. However, only two patients
who concomitantly received antiretroviral therapy
achieved sustained remission [2, 3]. Our patient
achieved stable complete remission with induction
therapy of ATRA and antracycline followed by re-
duced intensity consolidation therapy with ATRA, and
concomitant HAART.
This therapy had acceptable side effects and in-
duced a durable remission of APL in our patient, last-
ing for more than 14 months. ATRA treatment can be
complicated by the APL differentiation syndrome and
this diagnosis requires a high index of suspicion.
The patient’s HIV-1 viral load increased transiently
during interruption of HAART, but reintroduction of
therapy was soon followed by a good response (Fig. 1).
Based on evidence that ATRA can reduce HIV-1 viral
load by acting as RT-inhibitor [6], we can speculate that
it had additional positive impact in controlling HIV
disease. In addition, the patient is in remission of PC-
NSL for more than 47 months, with no signs of major
opportunistic disease and a good control of HIV plas-
ma viral load. However, during this follow-up his CD4
cell count did not rise above 200/mm3 (Fig. 1).
In conclusion, we showed that ATRA and idaru-
bicin based induction therapy followed by reduced in-
tensity consolidation therapy can be applied success-
fully in patients with HIV-associated APL. However,
the patient is still at a considerable risk for relapse and,
whenever possible, standard treatment for APL to-
gether with HAART should be used in HIV infected
patients.
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Fig. 1. The course of anti-
retroviral therapy, chemother-
apy, CD4 cells counts and vi-
ral load measurements over
time.
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